rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
16
|
pubmed:dateCreated |
2009-10-28
|
pubmed:abstractText |
In the prostate, androgens play a crucial role in normal and cancerous growth; hence the androgenic pathway has become a target of therapeutic intervention. Dutasteride is a 5 alpha-reductase (5AR) inhibitor currently being evaluated both for chemoprevention and treatment of prostate cancer. Dutasteride inhibits both 5AR I and II enzymes, effectively blocking conversion of testosterone to dihydrotestosterone (DHT) in the prostate. This greatly reduces the amount of the active ligand DHT available for binding to the androgen receptor (AR) and stimulating proliferation, making this a good candidate for chemoprevention of prostate cancer. In this study, we sought to determine how dutasteride is functioning at the molecular level, using a prostate cancer xenograft model.
|
pubmed:grant |
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-12429629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-12712403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-12925520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-14716738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-15166021,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-15371831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-15477368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-16043352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-16384856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-16818707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-17477363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-17573244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-17634540,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-17636412,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-17707058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-18079321,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-19164447,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19676081-9209391
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1097-0045
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright 2009 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:day |
1
|
pubmed:volume |
69
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1730-43
|
pubmed:dateRevised |
2011-5-12
|
pubmed:meshHeading |
pubmed-meshheading:19676081-Androgens,
pubmed-meshheading:19676081-Animals,
pubmed-meshheading:19676081-Azasteroids,
pubmed-meshheading:19676081-Cell Division,
pubmed-meshheading:19676081-Cholestenone 5 alpha-Reductase,
pubmed-meshheading:19676081-Delayed-Action Preparations,
pubmed-meshheading:19676081-Drug Implants,
pubmed-meshheading:19676081-Enzyme Inhibitors,
pubmed-meshheading:19676081-Gene Expression,
pubmed-meshheading:19676081-Male,
pubmed-meshheading:19676081-Mice,
pubmed-meshheading:19676081-Mice, Inbred BALB C,
pubmed-meshheading:19676081-Microarray Analysis,
pubmed-meshheading:19676081-Neoplasm Transplantation,
pubmed-meshheading:19676081-Prostatic Neoplasms,
pubmed-meshheading:19676081-Signal Transduction,
pubmed-meshheading:19676081-Transplantation, Heterologous,
pubmed-meshheading:19676081-Up-Regulation,
pubmed-meshheading:19676081-rho GTP-Binding Proteins
|
pubmed:year |
2009
|
pubmed:articleTitle |
Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.
|
pubmed:affiliation |
Department of Urology Research, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|